Cordis

Cordis Makes Strategic Investment in E2, a developer of Next-Generation Thrombectomy Devices

Retrieved on: 
Tuesday, April 5, 2022

MIAMI LAKES, Fla., April 5, 2022 /PRNewswire/ -- Cordis today announced a strategic investment venture that will expand the scope of the global cardiovascular technology company into the Venous Thromboembolism Market (VTM) with a strategic investment in Endovascular Engineering ("E2"), a developer of next-generation thrombectomy devices to treat patients with Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). 

Key Points: 
  • "Our investment in E2 positions Cordis at the vanguard of innovation in venous interventions," said Duke Rohlen, Executive Chairman of Cordis and CEO of Cordis-X, an independent accelerator created to drive innovation and growth for Cordis.
  • "We are proud to support the team's efforts to define a new standard of care for patients suffering from thromboembolism."
  • Cordis is partnering with SantVentures and another strategic investor in the E2 transaction.
  • The investment in E2 supports Cordis' legacy as a leader in creating lifesaving cardiovascular technologies."

InnovHeart appoints David Wilson as Chief Executive Officer

Retrieved on: 
Wednesday, March 30, 2022

NEWTON, Mass., March 30, 2022 /PRNewswire/ -- InnovHeart s.r.l., a developer of the novel Saturn Transcatheter Mitral Valve Replacement (TMVR) system for the treatment of mitral regurgitation, announced today the appointment of David James Wilson, an experienced healthcare and medical device executive as Chief Executive Officer of the company and executive member of the Board of Directors.

Key Points: 
  • NEWTON, Mass., March 30, 2022 /PRNewswire/ -- InnovHeart s.r.l., a developer of the novel Saturn Transcatheter Mitral Valve Replacement (TMVR) system for the treatment of mitral regurgitation, announced today the appointment of David James Wilson, an experienced healthcare and medical device executive as Chief Executive Officer of the company and executive member of the Board of Directors.
  • Mr. Wilson held other leadership roles at J&J companies, namely President of Mentor, Vice President of Ethicon R&D and Vice President of Ethicon Biosurgicals.
  • David's range of leadership skills will further enhance the commitment, drive and engineering prowess of the strong InnovHeart Team."
  • With David's guidance, we will succeed in raising the Saturn technology to become the pioneering technology in the TMVR space," said Giovanni Righini, founder and Chief Technology Officer of InnovHeart.

S.M.A.R.T. RADIANZ™ Vascular Stent System Approved for Transradial Use in the U.S.

Retrieved on: 
Thursday, March 10, 2022

RADIANZ Vascular Stent System, a self-expanding stent purposefully engineered for radial peripheral procedures.

Key Points: 
  • RADIANZ Vascular Stent System, a self-expanding stent purposefully engineered for radial peripheral procedures.
  • RADIANZ Vascular Stent System facilitates accurate, efficient placement of stents in the iliac and superficial femoral (SFA) arteries.
  • The newly approved vascular stent system joins the BRITE TIP RADIANZ Guiding Sheath and SABERX RADIANZ PTA Catheter to complete the RADIANZ Radial Peripheral System, specifically designed to optimize radial access, deliver exceptional outcomes, and high levels of patient satisfaction.
  • RADIANZ Vascular Stent Systemfeatures improved ergonomics and advanced one-handed deployment capability, offering excellent placement accuracy and up to 300% greater stability.

Pulnovo Medical Appoints Ms. Jessie Lian Jia as New CEO

Retrieved on: 
Thursday, March 10, 2022

SHANGHAI, March 10, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM innovative platform, recently announced the appointment of Ms. Jessie Lian Jia as Chief Executive Officer and Executive Director of the Board.

Key Points: 
  • SHANGHAI, March 10, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM innovative platform, recently announced the appointment of Ms. Jessie Lian Jia as Chief Executive Officer and Executive Director of the Board.
  • Ms. Lian subsequently moved toCardinalHealth to take on the position of General Manager of China and Vice President of Strategic Marketing for Asia Pacific.
  • Pulnovo Medical has thus far quickly established itself within the global medical devices industry with its innovation in China, but this is just the beginning.
  • I look forward to helping Pulnovo Medical achieve further success for the OTM platform, supported by the company's strong foundation in the industry."

DR. JEREMY DURACK AND DR. JOHN SIMPSON TO JOIN CORDIS-X INNOVATION ACCELERATOR

Retrieved on: 
Tuesday, January 18, 2022

"Recruiting Dr. John Simpson and Dr. Jeremy Durack, two of the greatest minds in cardiovascular science, will help us forge a bold new vision for Cordis."

Key Points: 
  • "Recruiting Dr. John Simpson and Dr. Jeremy Durack, two of the greatest minds in cardiovascular science, will help us forge a bold new vision for Cordis."
  • As Senior Advisor to Cordis-X, Dr. Simpson brings decades of scientific and commercial experience.
  • Dr. Jeremy Durack, an interventional radiologist and former Vice-Chair of Radiology at Memorial Sloan Kettering Cancer Center, will serve as Chief Clinical Officer for Cordis-X.
  • Cordis-X is an independent innovation accelerator with a streamlined go-to-market model built for speed, agility, and value maximization.

KKR Closes $4.0 Billion Health Care Strategic Growth Fund II

Retrieved on: 
Monday, January 10, 2022

KKR, a leading global investment firm, today announced the final closing of KKR Health Care Strategic Growth Fund II (HCSG II or the Fund), a $4.0 billion fund dedicated to health care growth equity investment opportunities primarily in North America and Europe.

Key Points: 
  • KKR, a leading global investment firm, today announced the final closing of KKR Health Care Strategic Growth Fund II (HCSG II or the Fund), a $4.0 billion fund dedicated to health care growth equity investment opportunities primarily in North America and Europe.
  • HCSG II is the successor fund to KKR Health Care Strategic Growth Fund (HCSG I), KKRs first dedicated health care growth equity vehicle, which held its final closing in November 2017 on $1.45 billion in capital commitments.
  • With a diversified portfolio approach, HCSG II will focus on the biopharmaceutical, medical device, health care services, life science tools / diagnostics, and health care information technology sub-sectors.
  • Now more than ever there is a significant demand both for innovative products and services in the health care sector and for an experienced and flexible capital partner to invest in their growth and further their reach, said Ali Satvat, Partner, Global Head of Health Care Strategic Growth, and Co-Head of Americas Health Care Private Equity at KKR.

CORDIS NAMES CHRISTOPHER SCULLY TO CFO POST

Retrieved on: 
Thursday, December 16, 2021

MIAMI LAKES, Fla., Dec. 16, 2021 /PRNewswire/ --Cordis, a global interventional cardiovascular technology company, today announced that Christopher Scully has joined the organization as Chief Financial Officer.

Key Points: 
  • MIAMI LAKES, Fla., Dec. 16, 2021 /PRNewswire/ --Cordis, a global interventional cardiovascular technology company, today announced that Christopher Scully has joined the organization as Chief Financial Officer.
  • Scully's appointment rounds out a dynamic new leadership team focused on reinvigorating Cordis' 62-year legacy of innovation.
  • "At Cordis, we are building a platform for medical device innovation that is possible only by tapping into the experience and insight of leaders like Chris Scully," said Cordis CEO Shar Matin.
  • "Cordis is a company with a rich history in cardiovascular technology, and I'm excited to be part of its dynamic path forward," said Scully.

Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors

Retrieved on: 
Monday, November 1, 2021

ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Seth H.Z.

Key Points: 
  • ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Seth H.Z.
  • "On behalf of the Esperion team and our directors, I am very pleased to welcome Seth to the Esperion board.
  • "Im honored to join Esperions board of directors during this transformational time ahead of the read-out of the unprecedented CLEAR Outcomes trial," said Mr. Fischer.
  • He currently serves as a member of the board of directors of Agile Therapeutics, Inc., Spectrum Pharmaceuticals, Inc., and Marinus Pharmaceuticals.

The Cordish Companies Announces Two Key Executive Hires To Cordish Gaming Group As Division Expands To Accommodate Growth

Retrieved on: 
Tuesday, July 20, 2021

BALTIMORE, July 20, 2021 /PRNewswire/ --The Cordish Companies today announced two key executive hires to Cordish Gaming Group, the gaming division of the Company.

Key Points: 
  • BALTIMORE, July 20, 2021 /PRNewswire/ --The Cordish Companies today announced two key executive hires to Cordish Gaming Group, the gaming division of the Company.
  • Cordish Gaming is also exploring and activating new ventures in igaming and sports betting.
  • The Cordish Companies has developed and operates highly acclaimed dining, entertainment and hospitality destinations throughout the United States, many falling under The Cordish Companies' Live!
  • "The Cordish Companies," "The Cordish Company" and "Cordish" are trademarks used under license by independent corporations, legal liability companies and partnerships ("Cordish Entities").

Artio Medical Welcomes Clinical, Regulatory, and Quality Executives

Retrieved on: 
Wednesday, July 14, 2021

De Peralta comes to Artio from ExThera Medical Corporation where he served as the Vice President for Regulatory and Clinical Affairs.

Key Points: 
  • De Peralta comes to Artio from ExThera Medical Corporation where he served as the Vice President for Regulatory and Clinical Affairs.
  • Dale joins Artio with over 30 years of quality assurance experience for medical device companies.
  • Prior to Confluent Medical, Dale held quality leadership roles with BioInspire Technologies, Cordis, Covidien, LifeScan, Inc, and Varian Medical Systems.
  • "We are excited to welcome Erdie and Delane to the Artio team", said Dr. F. Nicholas Franano, President and CEO of Artio Medical.